| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $8,161,468 | 31 | 100 |
| Napolitano Janet | director | 0 | $0 | 1 | $30,240 | $-30,240 |
| Eisner Mark | EVP and Chief Medical Officer | 0 | $0 | 3 | $49,524 | $-49,524 |
| O'Byrne Jason | EVP & Chief Financial Officer | 0 | $0 | 3 | $68,927 | $-68,927 |
| Sabatini Brent | SVP, Chief Accounting Officer | 0 | $0 | 5 | $113,087 | $-113,087 |
| de Verneuil Vanina | EVP and General Counsel | 0 | $0 | 5 | $217,684 | $-217,684 |
| De Backer Marianne | Chief Executive Officer | 0 | $0 | 3 | $946,964 | $-946,964 |
| SATO VICKI L | director | 0 | $0 | 8 | $1.6M | $-1.6M |
| SVF Endurance (Cayman) Ltd | 10 percent owner | 0 | $0 | 5 | $5.27M | $-5.27M |
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency …
Over the last 12 months, insiders at Vir Biotechnology, Inc. have bought $0 and sold $8.16M worth of Vir Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Vir Biotechnology, Inc. have bought $123,670 and sold $46.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $56,816 was made by Sigal Charles Elliott (director) on 2023‑03‑01.
| 2026-06-01 | Sale | Sabatini Brent | SVP, Chief Accounting Officer | 379 0.0002% | $9.45 | $3,582 | +12.68% | |
| 2026-06-01 | Sale | Napolitano Janet | director | 3,200 0.002% | $9.45 | $30,240 | +12.68% | |
| 2026-05-01 | Sale | SATO VICKI L | director | 22,000 0.0137% | $10.05 | $221,025 | -0.70% | |
| 2026-04-06 | Sale | De Backer Marianne | President and CEO | 72,559 0.0459% | $9.16 | $664,350 | +10.49% | |
| 2026-04-01 | Sale | SATO VICKI L | director | 22,000 0.0138% | $9.07 | $199,617 | +10.86% | |
| 2026-03-23 | Sale | Sabatini Brent | SVP, Chief Accounting Officer | 7,711 0.005% | $9.12 | $70,324 | +12.33% | |
| 2026-03-02 | Sale | SATO VICKI L | director | 22,000 0.0165% | $9.51 | $209,181 | +4.60% | |
| 2026-02-25 | Sale | Eisner Mark | EVP and Chief Medical Officer | 1,889 0.0013% | $9.82 | $18,550 | -3.00% | |
| 2026-02-25 | Sale | de Verneuil Vanina | EVP, General Counsel, Corp Sec | 13,700 0.0097% | $9.82 | $134,534 | -3.00% | |
| 2026-02-24 | Sale | SATO VICKI L | director | 42,377 0.0313% | $9.75 | $413,366 | +2.42% | |
| 2026-02-24 | Sale | De Backer Marianne | Chief Executive Officer | 14,762 0.0107% | $9.53 | $140,720 | +2.42% | |
| 2026-02-24 | Sale | O'Byrne Jason | EVP & Chief Financial Officer | 1,634 0.0012% | $9.53 | $15,576 | +2.42% | |
| 2026-02-24 | Sale | Eisner Mark | EVP and Chief Medical Officer | 1,616 0.0012% | $9.53 | $15,405 | +2.42% | |
| 2026-02-24 | Sale | de Verneuil Vanina | EVP, General Counsel, Corp Sec | 3,117 0.0023% | $9.53 | $29,713 | +2.42% | |
| 2026-02-24 | Sale | Sabatini Brent | SVP, Chief Accounting Officer | 1,430 0.001% | $9.53 | $13,632 | +2.42% | |
| 2026-02-23 | Sale | De Backer Marianne | Chief Executive Officer | 19,039 0.0137% | $7.45 | $141,894 | +30.55% | |
| 2026-02-23 | Sale | O'Byrne Jason | EVP & Chief Financial Officer | 2,089 0.0015% | $7.45 | $15,569 | +30.55% | |
| 2026-02-23 | Sale | Eisner Mark | EVP and Chief Medical Officer | 2,089 0.0015% | $7.45 | $15,569 | +30.55% | |
| 2026-02-23 | Sale | de Verneuil Vanina | EVP, General Counsel, Corp Sec | 4,445 0.0032% | $7.45 | $33,128 | +30.55% | |
| 2026-02-23 | Sale | Sabatini Brent | SVP, Chief Accounting Officer | 1,829 0.0013% | $7.45 | $13,631 | +30.55% |
| SVF Endurance (Cayman) Ltd | 10 percent owner | 13728924 8.1133% | $154.04M | 1 | 99 | +115.34% |
| Alaska Permanent Fund Corp | 10 percent owner | 5555556 3.2831% | $62.33M | 1 | 0 | +115.34% |
| Temasek Holdings (Private) Ltd | 10 percent owner | 5499999 3.2503% | $61.71M | 1 | 0 | +115.34% |
| Abu Dhabi Investment Authority | 3666666 2.1669% | $41.14M | 1 | 0 | +115.34% | |
| NELSEN ROBERT | 1000000 0.591% | $11.22M | 1 | 0 | +115.34% | |
| Burow Kristina | director | 1000000 0.591% | $11.22M | 1 | 0 | +115.34% |
| ARCH Venture Partners IX, LLC | 10 percent owner | 1000000 0.591% | $11.22M | 1 | 0 | +115.34% |
| HANLY ANN M. | EVP & Chief Technology Officer | 117901 0.0697% | $1.32M | 1 | 6 | <0.0001% |
| PATRICK DONALD A | director | 52000 0.0307% | $583,440.00 | 1 | 0 | |
| Sigal Charles Elliott | director | 10000 0.0059% | $112,200.00 | 4 | 0 | <0.0001% |
$607,395,062 | 99 | 4.23% | $1.88B | |
$21,345,882 | 83 | 94.45% | $2.19B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B |
| Increased Positions | 97 | +36.19% | 19M | +17.45% |
| Decreased Positions | 113 | -42.16% | 10M | -9.52% |
| New Positions | 34 | New | 13M | New |
| Sold Out Positions | 32 | Sold Out | 1M | Sold Out |
| Total Postitions | 252 | -5.97% | 116M | +7.93% |
| Sb Investment Advisers (Uk) Ltd | $99,103.00 | 12% | 16.68M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $94,848.00 | 11.49% | 15.97M | -185,534 | -1.15% | 2025-09-30 |
| Arch Venture Management, Llc | $76,725.00 | 9.29% | 12.92M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $76,028.00 | 9.21% | 12.8M | -427,685 | -3.23% | 2025-09-30 |
| State Street Corp | $31,133.00 | 3.77% | 5.24M | -13,419 | -0.26% | 2025-09-30 |
| Fmr Llc | $21,605.00 | 2.62% | 3.64M | +78,475 | +2.21% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $17,694.00 | 2.14% | 2.98M | -29,084 | -0.97% | 2025-09-30 |
| Morgan Stanley | $15,973.00 | 1.94% | 2.69M | +1M | +64.6% | 2025-09-30 |
| Orbimed Advisors Llc | $14,141.00 | 1.71% | 2.38M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $13,343.00 | 1.62% | 2.25M | -6,198 | -0.28% | 2025-09-30 |